RecruitingPhase 3NCT07335211

Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension


Sponsor

Huons Co., Ltd.

Enrollment

206 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension


Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new eye drop treatment called HUC3-637 in adults with primary open-angle glaucoma or elevated eye pressure (ocular hypertension) — conditions that can damage vision if not treated. **You may be eligible if...** - You are 19 or older - You have been diagnosed with primary open-angle glaucoma or elevated eye pressure (ocular hypertension) - You are able to understand and voluntarily consent to participate **You may NOT be eligible if...** - You have a different type of glaucoma (e.g., acute or chronic angle-closure glaucoma, congenital or secondary glaucoma) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHUC3-637

Ophthalmic solution instilled directly into the eye (topical ocular administration)

DRUGHUC3-637-R

Ophthalmic solution instilled directly into the eye (topical ocular administration)


Locations(1)

Kangbuk Samsung Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07335211


Related Trials